The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Titova N.V.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnology

Katunina E.A.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Live at

Authors:

Titova N.V., Katunina E.A.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(5‑6): 22‑30

Read: 180 times

To cite this article:

Titova NV, Katunina EA. Live at. Non Nocere. New Therapeutic Journal. 2025;(5‑6):22‑30. (In Russ.)

References:

  1. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12.  https://doi.org/10.1016/j.cger.2019.08.002
  2. Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson’s Syndrome. Annu Rev Pathol. 2023 Jan 24;18:95-121.  https://doi.org/10.1146/annurev-pathmechdis-031521-034145
  3. Jellinger KA. The pathomechanisms underlying Parkinson’s disease. Expert Rev Neurother. 2014 Feb;14(2):199-215.  https://doi.org/10.1586/14737175.2014.877842
  4. Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci. 2010 Jan;1184:188-195.  https://doi.org/10.1111/j.1749-6632.2009.05118.x
  5. Jellinger KA. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm (Vienna). 2019 Apr;126(4):423-431.  https://doi.org/10.1007/s00702-018-1898-9
  6. Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes – key to understanding heterogeneity. Nat Rev Neurol. 2021 Jun;17(6):349-361.  https://doi.org/10.1038/s41582-021-00486-9
  7. Palakurthi B, Burugupally SP. Postural Instability in Parkinson’s Disease: A Review. Brain Sci. 2019 Sep 18;9(9):239.  https://doi.org/10.3390/brainsci9090239
  8. Gao C, Liu J, Tan Y, Chen S. Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments. Transl Neurodegener. 2020 Apr 15;9:12.  https://doi.org/10.1186/s40035-020-00191-5
  9. Abusrair AH, Elsekaily W, Bohlega S. Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies. Tremor Other Hyperkinet Mov (N Y). 2022 Sep 13;12:29.  https://doi.org/10.5334/tohm.712
  10. Munhoz RP, Tumas V, Pedroso JL, Silveira-Moriyama L. The clinical diagnosis of Parkinson’s disease. Arq Neuropsiquiatr. 2024 Jun;82(6):1-10.  https://doi.org/10.1055/s-0043-1777775
  11. Opara J, Małecki A, Małecka E, Socha T. Motor assessment in Parkinson`s disease. Ann Agric Environ Med. 2017 Sep 21;24(3):411-415.  https://doi.org/10.5604/12321966.1232774
  12. Jellinger KA. Neuropathology of Nonmotor Symptoms of Parkinson’s Disease. Int Rev Neurobiol. 2017;133:13-62.  https://doi.org/10.1016/bs.irn.2017.05.005
  13. Akbar U, D’Abreu A, Friedman JH. Nonmotor Symptoms in Parkinson’s Disease. Semin Neurol. 2017 Apr;37(2):158-166.  https://doi.org/10.1055/s-0037-1602424
  14. Shipilova N.N., Titova N.V., Katunina E.A. The problem of non-motor symptoms of Parkinson’s disease and the effect of dopaminergic therapy on their correction. RMJ. 2018. No. 4(II). P. 85–90. 
  15. Pötter-Nerger M, Schrader C, Jost WH, Höglinger G. The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states. J Neural Transm (Vienna). 2024 Oct;131(10):1199-1207. https://doi.org/10.1007/s00702-024-02817-8
  16. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591-1601. https://doi.org/10.1002/mds.26424
  17. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The ‘swallow tail’ appearance of the healthy nigrosome – a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014 Apr 7;9(4): e93814. https://doi.org/10.1371/journal.pone.0093814
  18. Meijer FJ, Goraj B. Brain MRI in Parkinson’s disease. Front Biosci (Elite Ed). 2014 Jun 1;6(2):360-369.  https://doi.org/10.2741/E711
  19. Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond). 2016 Aug;16(4):371-375.  https://doi.org/10.7861/clinmedicine.16-4-371
  20. Bor-Seng-Shu E, Pedroso JL, Andrade DC, et al. Transcranial sonography in Parkinson’s disease. Einstein (Sao Paulo). 2012 Apr–Jun;10(2):242-246. English, Portuguese. https://doi.org/10.1590/s1679-45082012000200022
  21. Caproni S, Colosimo C. Diagnosis and Differential Diagnosis of Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):13-24.  https://doi.org/10.1016/j.cger.2019.09.014
  22. Hirsch MA, Iyer SS, Sanjak M. Exercise-induced neuroplasticity in human Parkinson’s disease: What is the evidence telling us? Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S78-81.  https://doi.org/10.1016/j.parkreldis.2015.09.030
  23. Langeskov-Christensen M, Franzén E, Grøndahl Hvid L, Dalgas U. Exercise as medicine in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2024 Oct 16;95(11):1077-1088. https://doi.org/10.1136/jnnp-2023-332974
  24. Church FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease. Biomolecules. 2021 Apr 20;11(4):612.  https://doi.org/10.3390/biom11040612
  25. Elsworth JD. Parkinson’s disease treatment: past, present, and future. J Neural Transm (Vienna). 2020 May;127(5):785-791.  https://doi.org/10.1007/s00702-020-02167-1
  26. Wang R, Shih LC. Parkinson’s disease – current treatment. Curr Opin Neurol. 2023 Aug 1;36(4):302-308.  https://doi.org/10.1097/WCO.0000000000001166
  27. Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson’s Disease. Semin Neurol. 2017 Apr;37(2):147-157.  https://doi.org/10.1055/s-0037-1602423
  28. Катунина Е.А., Титова Н.В. Леводопа-индуцированные дискинезии при болезни Паркинсона: патогенез, клиника, подходы к лечению. Фарматека. 2014;10(3):58-69. 
  29. Malek N. Deep Brain Stimulation in Parkinson’s Disease. Neurol India. 2019 Jul–Aug;67(4):968-978.  https://doi.org/10.4103/0028-3886.266268
  30. Tsunemi T, Oyama G, Saiki S, et al. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson’s Disease: A Systematic Review. Mov Disord. 2021 Aug;36(8):1759-1771. https://doi.org/10.1002/mds.28595
  31. Wagner MJ, Daniel CP, Plaisance CJ, et al. Apomorphine for Parkinson’s disease: pharmacologic and clinical considerations. Expert Opin Emerg Drugs. 2023 Dec;28(4):275-281.  https://doi.org/10.1080/14728214.2023.2278677
  32. Titova NV, Katunina EA, Tairova RT, Senko IV, Dzhafarov VM, Malykhina EA. The problem of pharmacoresistant tremor in Parkinson’s disease and essential tremor. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10):24-30. (In Russ.) https://doi.org/10.17116/jnevro202212210124
  33. Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson’s disease. Mol Med. 2021 Feb 25;27(1):17.  https://doi.org/10.1186/s10020-021-00279-2

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.